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Abstract: Several recent studies have emphasized a crucial role for the nitrergic system in movement control and the pathophysiology of 
the basal ganglia (BG). These observations are supported by anatomical evidence demonstrating the presence of nitric oxide synthase 
(NOS) in all the basal ganglia nuclei. In fact, nitrergic terminals have been reported to make synaptic contacts with both substantia nigra 
dopamine-containing neurons and their terminal areas such as the striatum, the globus pallidus and the subthalamus. These brain areas 
contain a high expression of nitric oxide (NO)-producing neurons, with the striatum having the greatest number, together with important 
NO afferent input. In this paper, the distribution of NO in the BG nuclei will be described. Furthermore, evidence demonstrating the 
nitrergic control of BG activity will be reviewed. The new avenues that the increasing knowledge of NO in motor control has opened for 
exploring the pathophysiology and pharmacology of Parkinson’s disease and other movement disorders will be discussed. For example, 
inhibition of striatal NO/guanosine monophosphate signal pathway by phosphodiesterases seems to be effective in levodopa-induced 
dyskinesia. However, the results of experimental studies have to be interpreted with caution given the complexities of nitrergic signalling 
and the limitations of animal models. Nevertheless, the NO system represents a promising pharmacological intervention for treating 
Parkinson’s disease and related disorders. 
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1. INTRODUCTION 
 Nitric oxide (NO) has been associated with a variety of 
physiological and pathological processes in the human body since it 
was identified as a novel signal molecule by Furchgott and 
Zawadzki [1]. NO is synthesized from L-arginine (L-ARG) by a 
nitric oxide synthase (NOS) using nicotinamide adenine 
dinucleotide phosphate (NADPH) and molecular oxygen [2]. To 
date, 3 isoforms of NOS, that is, neuronal NOS (nNOS), endothelial 
NOS (eNOS), and inducible NOS (iNOS), have been identified. 
While nNOS and eNOS are constitutively expressed, the expression 
of iNOS is induced through the inflammatory response process of 
cells to infections or injuries [3]. The characteristics of 
neurotransmitter NO are: (i) it is synthesized postsynaptically, (ii) it 
is not stored in vesicles being a diffusible gas, (iii) it does not act at 
conventional receptors on the surface of adjacent neurons, (iv) it 
can act as a retrograde messenger diffusing to the presynaptic 
terminal. Based on this evidence we can affirm that NO in the 
nervous system works as an unorthodox neurotransmitter. A major 
biochemical function of NO is to activate the soluble form of 
guanylyl cyclase (sGC), inducing the accumulation of cyclic 
guanosine monophosphate (cGMP) in target cells. cGMP 
subsequently acts via protein kinases, phosphodiesterases, and 
perhaps directly on ion channels [4, 5]. Furthermore, NO can exert 
its biological effects through other mechanisms, such as modulating 
the function of monoamine transporters and S-nitrosylation of 
receptors. It has been demonstrated that NO can S-nitrosylate the 
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N-methyl-D-aspartate (NMDA) receptor leading to its down-
regulation [6]. We will review the compelling evidence showing a 
pivotal role for NO in motor behaviour through the modulation of 
the basal ganglia circuitry. 
2. OVERVIEW OF BASAL GANGLIA ANATOMY AND 
FUNCTIONS 
 The basal ganglia (BG) are the largest subcortical nuclei of the 
vertebrate brain including human forebrain, and they are placed in a 
key position to influence motor behaviour, emotions, and cognition 
[7]. Our understanding of the BG circuits remains incomplete, 
although knowledge has grown rapidly during the last decades. The 
overview presented here is simplified and mainly limited to the 
aspects most relevant to the discussion. The BG in the vertebrate 
brain consist of several different nuclei, the striatum, the external 
segment of the globus pallidus (GPe), the internal segment of the 
globus pallidus (GPi) and its equivalent in rodents, the 
entopeduncular nucleus, the subthalamic nucleus (STN) and the 
substantia nigra (SN), each of these being profoundly important 
clinically [8, 9]. Recently, it has been suggested that the 
pedunculopontine nucleus of the brainstem should be considered as 
part of the BG as well [10]. Indeed, it is anatomically and 
physiologically associated with them and affects the function of 
several nuclei in the BG circuits [10]. The striatum (or caudate-
putamen) is the main input nucleus, which receives topographical 
excitatory projections from almost the entire cerebral cortex, 
especially from the sensorimotor and frontal cortex [11]. The 
striatum and the downstream structures in the BG are organised in 
2      CNS & Neurological Disorders - Drug Targets, 2011, Vol. 10, No. 7 Pierucci et al. 
topographically and functionally segregated pathways. The cortical 
inputs to the striatum are convergent, in such a way, for example, 
that sensory and motor cortex areas converge into single striatal 
zones [12]. Close to the striatum is located the GPi and the 
substantia nigra pars reticulata (SNr), the main output nuclei of the 
BG [13]. They project, via various thalamic nuclei, to most cortical 
areas of the frontal lobe [14]. This architecture means that the BG 
are part of extensive loops, BG-thalamocortical circuits, which link 
almost the entire cerebral cortex to the frontal lobe. The GPi and the 
SNr also have descending output to the brain stem, especially with 
the pedunculopontine tegmental (PPT) nucleus. 
 The striatum can be divided into three main parts: the putamen, 
the caudate nucleus, and the ventral striatum. This division roughly 
corresponds to a functional division of BG-thalamocortical circuits: 
sensory-motor circuits of the putamen, with output to primary 
motor cortex, the supplementary motor cortex and the premotor 
cortex; associative circuits of the caudate nucleus, with output to 
the prefrontal cortex; and limbic circuits of the ventral striatum, 
with output to the anterior cingulate cortex and medial prefrontal 
cortex [13, 15]. The ventral (limbic) striatum also receives input 
from limbic structures, such as the amygdala and hippocampus 
[16]. The striatum projects to the output structures (GPi and SNr) 
by two pathways, the so-called direct and indirect pathways. The 
indirect pathway also includes the STN. All projections from the 
striatum, the GPe, the GPi and SNr release ?-aminobutyric acid 
(GABA) and are inhibitory, while the projections from the cortex, 
the STN and the thalamus are excitatory, and use glutamate (GLU) 
as their neurotransmitter. The GABA-containing neurons in the GPi 
and the SNr are tonically active, they project to the ventral tier of 
the thalamus (ventrolateral, ventromedial, ventral anterior nuclei) 
and form inhibitory synaptic contacts with thalamocortical neurons 
that project to the motor and premotor cortex. Activation of the 
direct pathway inhibits GPi/SNr neurons, which in turn disinhibits 
thalamic neurons, finally resulting in excitation of the cortical 
neurons. Activation of the indirect pathway has an opposite effect, 
activating the GPi/SNr and thereby inhibiting the cortex [13]. In 
this way, the two pathways balance each other, modulating cortical 
activity. Alexander and Crutcher [14] suggested a model where the 
indirect pathway provides a diffuse background inhibition of 
behavioural impulses, while the direct pathway gives a focused 
activation of the desired behavioural program. In this model, the 
BG play an important role in inhibiting potentially competing motor 
programs. This may be a general mechanism for action selection 
where “the winner takes all”, by facilitation of the strongest cortical 
signal and suppression of the rest [17]. Recently, it has been 
proposed by Wilkström and co-workers that the BG can also elicit a 
behaviourally meaningful and varied motor pattern without the 
involvement of the cerebral cortex [18]. 
 Among the BG nuclei, the striatum seems to have a prominent 
role in determining when a given motor program should be selected 
and called into action. For the hypothesised function of the striatum 
in selection of motor programs, a certain level of tonic dopamine 
(DA) activity is required. DA projections from the substantia nigra 
pars compacta (SNc) to the striatum modulate the activity of striatal 
neurons in a complex way. According to a simplified model, the 
striatal neurons forming the direct pathway mainly express 
excitatory D1-receptors, while the striatal neurons in the indirect 
pathway mainly have inhibitory D2-receptors. This means that DA 
would facilitate motor behaviours through the activation of the 
direct pathway and conversely through the inhibition of the indirect 
one. Reduced DA innervation of the striatum results, indeed, in 
hypokinesia and difficulty in initiating different motor patterns, 
including facial expression [19]; enhanced striatal DA activity will 
instead give rise to hyperkinesia (i.e. premature or unintended 
activation of motor programs). DA also seems to be involved in BG 
learning processes, by strengthening or weakening the efficacy of 
corticostriatal synapses [8, 20, 21]. In this way the striatum may 
learn to respond to certain patterns of cortical activation. 
3. NO DISTRIBUTION IN THE BG 
 NO signalling plays an important role in controlling motor 
behaviour modulating the integration of information processed by 
the BG nuclei. Most likely, it interacts with dopaminergic 
(DAergic), serotonergic, cholinergic and glutamatergic (GLUergic) 
neurotransmission at different levels of these nuclei. Consistently, 
mice mutant for nNOS have altered locomotor abilities and rats and 
mice treated with various NOS inhibitors show problems with fine 
motor control. NO, furthermore, antagonizes the increase in 
locomotor activity found after DA agonist administration. The 
pharmacological blocking of nNOS decreases locomotion and 
induces catalepsy in different animal species [22]. 
 Although NOS neurons are present throughout all BG nuclei 
and in other regions involved in motor control such as the motor 
cortices and the PPT, their concentration varies significantly [5, 22-
28]. For example, in comparison with other brain centers, the SNc 
may be considered a rather NOS cell-poor nucleus [29, 30]. Some 
studies even failed to detect any NADPH-diaphorase (NADPH-d) 
(+) cells in the SNc [31]. Indeed, most NOS is contained in 
afferents from the PPT nucleus [32, 33], while only a small NOS+ 
neuronal population has been identified within the ventral 
tegmental area (VTA) and the SNc [29, 34, 35]. 
 The sequential staining for NOS and tyrosine hydroxylase (TH) 
indicated that these enzymes are colocalized in less than 1% of the 
neurons positive for either marker [29, 30, 35]. Contrasting results 
have been shown in VTA by Klejbor and co-workers, revealing a 
higher percentage of NOS+ neurons ranging from 9 to 22% [34]. 
Similarly, some evidence seems to suggest that the SNc NOS+ 
neuron population is higher and has almost the same density as 
those present in the ventral pallidus and nucleus accumbens [36, 
37]. Thus, such data provide grounds for a production of NO by 
DAergic cells, together with an afferent NO input that could affect 
DA neurons through diffusion from neighbouring sources. 
Strikingly, NOS+ neuron numbers within the SNc and the BG in 
general are subject to modification, for example nigral nitrergic 
neurons increase after intoxication with 1-methyl 4-phenyl 1,2,3,6-
tetrahydropyridine (MPTP) [38] and rotenone [39] but decreases 
after 30 and 50 days from 6-hydroxydopamine (6-OHDA) 
administration [40]. 
 The scenario appears different in the SNr; in fact many 
NADPH-d (+) dendrites and axon-like processes are present, some 
of which have close relationships with vessels [31]. The origin of 
these dendrites and axon-like processes may be local, constituted by 
an ample intrinsic subpopulation of SNr GABA/NOS neurons, and 
extrinsic, constituted by medium to large cholinergic/NOS neurons 
of the PPT and lateraldorsal tegmental nucleus [30]. Within the SNr 
two types of GABA-cells co-express NOS: one is represented by 
large cells in the rostrolateral part of the SNr containing 
parvalbumin and NOS and another population constituted by small 
GABA-cells located in the rostromedial portion of the SNr [30]. 
 NOS expression in the striatum has been more extensively 
studied [23, 24, 26-28, 31, 41, 42]. NOS neurons are one type of the 
four different classes of interneurons present in rodent and human 
striatum. They populate the entire striatum, including the tail and 
gyrus of the caudate nucleus, and represent 1-2% of all striatal cells 
and are spiny, co-expressing neurokinin 1-receptors, somatostatin 
(SOM) and neuropeptide Y (NPY) [28]. The striatal nitrergic 
neurons are essentially small in diameter (12-25 ?m), slender, 
bipolar and fusiform with a long dendrite. The neuronal population 
of the human striatum seems to be more heterogeneous than 
previously thought. In fact, up to 12 different subtypes of NOS 
neurons have been described in humans and, strikingly, one of them 
is a large reticular NOS cell that resembles the characteristics of a 
projecting neuron [42]. This efferent nitrergic cell was  
 
 
Nitric Oxide Modulation of the Basal Ganglia Circuitry CNS & Neurological Disorders - Drug Targets, 2011, Vol. 10, No. 7     3 
demonstrated to project to the insular cortex. Thus, at least some of 
the NOS reticular neurons of the human striatum have direct 
cortical projections, though the existence of their axon collaterals in 
striatal tissues close to the maternal cells also demonstrates that 
they influence surrounding cells [26]. Moreover, the matrix is the 
striatal compartment with the densest NOS neuronal population that 
tends to be located at the boundaries between the striosomes and the 
matrix, as well as at the boundaries between the core and the 
peripheral region of the striosomes [41]. This finding has an 
important functional implication, because the NOS neurons that 
occur at the edges between the two compartments are thought to 
mediate interactions between the medium spiny neurons (MSNs) of 
the matrix and the striosomes. 
 Despite recent advances, the role of NOS interneurons in the 
striatum is still not clear. Among their postulated functions are: (i) 
to control local blood flow in the striatum by releasing NO acting 
directly on sGC in the vascular smooth-muscle and causing 
vasodilatation; (ii) to produce NO that acts as a neurotransmitter 
modulating striatal discharge and plasticity, either through direct 
interactions with ligand-gated channels or by influencing 
surrounding striatal MSNs via the stimulation of second messenger 
systems [43]. 
 mRNA expression studies have revealed a scattered sub-
population of NOS neurons in the internal segment and medial 
medullary lamina (MML) of the globus pallidus (GP) and in almost 
all neurons of the STN, which are presumed to be GLUergic and 
excitatory. Moreover, it is important to note that NOS neurons have 
not been detected in the GPe and this may have functional 
implications, since it is the GPi and not the GPe which relays the 
BG output to the motor nuclei of the thalamus. In the GP, NO is 
probably co-localized with GABA, which has previously been 
shown to be the neurotransmitter of virtually all pallidal neurons 
[24, 27]. 
4. NO MODULATION OF BG CIRCUITRY 
4.1 NO MODULATION of the Activity of Daergic Nigrostriatal 
System 
 Experimental evidence from a wealth of studies have shown 
that the NO system plays a prominent role in the control of central 
nigrostriatal DA function [43-48]. This experimental evidence is 
corroborated by anatomical localization of NOS in the ventral 
midbrain (see the discussion above). 
 NO modulation of DA nigrostriatal system has been intensive 
studied, especially with a neurochemical approach producing 
confounding results [43]. Both excitatory and inhibitory control by 
NO of striatal DA release has been described. Indeed, the role of 
NO in striatal DA release is one of the most controversial in 
neuroscience and enhancement is the commonly accepted effect 
[43]. However, a reconciliatory hypothesis has been suggested that 
NO acts to decrease DA release when the biological system is not 
in a state of oxidative stress [49, 50]. In contrast, under 
physiological conditions, NO might facilitate DA release. 
Nevertheless, neurochemical data obtained in our laboratory concur 
with the electrophysiological recordings, also showing that 
variation of endogenous nitrergic tone does not influence basal 
striatal DA release [44, 46, 47]. On the other hand, 
electrophysiological [44, 47, 51] evidence, although scanty, is 
compelling and shows a lack of tonic nitrergic control over the DA 
neuronal discharge both in vivo [44, 47, 52] and in vitro [51, 52] 
(Fig. 1). These studies have instead indicated a possible state-
dependent facilitatory control of NO on the nigrostriatal DA  
pathway. Indeed, N?-nitro-L-arginine methyl ester (L-NAME), an 
unselective NOS inhibitor, and the NO precursor L-ARG, inhibits 
and potentiates, respectively, NMDA-induced [51] increase of DA 
firing and bursting rate and had no effect in basal conditions in 
vitro. Similar results have been obtained in vivo: disruption of NO 
levels by general treatment or local application by 
microiontophoresis with L-NAME, L-ARG and the NO donor 
molsidomine (MOL) produced consistent changes in the firing rate 
and burst firing of SNc DA neurons [44]. Consistent with a block of 
NMDA-induced bursts in vitro by NOS inhibition [51], disrupting 
NO endogenous tone counteracted the stimulation induced by 
nicotine in the SNc [44] and in VTA [52] (see [53] for the nicotine 
effect in the DA function). 7-nitro-indazolone (7-NI) and L-NAME 
pretreatment completely prevented the increase in DA neuronal 
firing rate and burst firing induced by nicotine administration in the 
SNc and attenuated nicotine-induced enhancement of the 
extracellular levels of DA and 3,4-dihydroxy-phenylacetic acid 
(DOPAC) in the striatum of awake freely moving rats [44]. 
Moreover, the critical role played by NO in nigral nicotine/DA 
interaction is further supported by the evidence of a complete 
restoration of nicotine effects in rats pre-treated with 7-NI and L-
NAME, plus the NO donor MOL. 
 The electrophysiological and neurochemical effects of 7-NI on 
the nigrostrial system are more complex and deserve more attention 
owing to the peculiarity of the molecule. 7-NI is a common 
pharmacological tool used to study NO effect in the central nervous 
system (CNS) since it preferentially inhibits nNOS in vivo [54] and 
above all it does not have any appreciable confounding pressor 
effects as does L-NAME [55]. However, 7-NI shows a strong 
monoamine oxidase (MAO) type B inhibitory activity [56-59]. 
Indeed, the effects obtained with 7-NI may be due not only to 
inhibition of neuronal NOS, but also, at least in part, to MAO 
inhibition suggesting that in general the results obtained with this 
NOS inhibitors should be taken cautiously. 
 Differently from L-NAME that was ineffective, although not 
significant in the overall statistical analysis, 7-NI treatment slightly 
decreased discharge rate and 2 DA neurons out of 6 were clearly 
affected in their firing pattern, showing a long-lasting decrease in 
the number of spikes fired in bursts [44]. In a SNc cells-per-track 
study, 7-NI significantly decreased the percentage of action 
potentials fired in bursts while the number of spontaneously active 
nigral DA neurons and the mean firing rate of these cells were 
unaffected [47]. In addition, 7-NI-induced a decrease of DOPAC 
[44, 47, 59]. All these effects are likely to be independent of nNOS 
inhibition or more generally of NO production and instead are a 
consequence of MAO B inhibitory activity possessed by 7-NI. 
Indeed, it has been shown that the MAO B inhibitor deprenyl 
decreases the spontaneous firing discharge of DA SNc and VTA 
cells in vitro [60] and striatal DOPAC [59]. 
 Increasing NO levels within the SNc seems ineffective as well 
on the nigral neuron firing pattern. MOL, although capable of 
inducing a significant increase in the number of spontaneously 
active SNc neurons, did not modify nigral burst and firing in a 
population study [47], and did not change firing rate and pattern 
[44], confirming the L-ARG lack of effect seen in vivo [52] and in 
vitro [51]. Therefore, NO may be necessary, but not sufficient, for 
the induction of burst firing. 
 Surprisingly, a single MOL injection instead decreased both 
striatal DA tissue levels and DA metabolism, although the latter not 
significantly [47]. This evidence would suggest that NO has an 
inhibitory effect on striatal DA efflux in accordance with some 
previous studies [48]. Indeed, we have revealed an exacerbated 
effect on DA tissue levels in the 6-OHDA model of Parkinson’s 
disease (PD) produced by MOL [46], a toxin that induces 
degeneration of nigrostriatal DA-containing neurons by producing 
reactive oxygen species [61]. 
 Furthermore, an interesting observation arising from [47] was 
that repeated (4 days) 7-NI and MOL administration affected 
nigrostriatal neurotransmission differently. Sub-chronic MOL 
treatment failed to modify either the number of spontaneously 
active neurons or other electrophysiological parameters. 
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Conversely, striatal DA and DOPAC levels were still decreased 
[47]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Effect of nitric oxide drugs on the firing rate of dopaminergic 
neurons in vitro. Recording from a DA cell shows enhancement of burst 
firing by L-arginine (100 mM) (A). L-NAME (100 mM) selectively inhibits 
NMDA-induced burst firing in DA neurons (B). D-NAME (100 mM), the 
less potent enantiomer for inhibition of NOS, fails to inhibit NMDA-
induced burst firing (C). L-NAME-induced inhibition of burst firing is 
reversed by the addition of L-arginine (100 mM) to the perfusate (D). 
Broken lines indicate -50 mV. Modified from [51]. 
 Strikingly, the inhibition of NOS by 7-NI produced an 
unexpected significant rise in the number of spontaneously active 
nigral neurons and a correlated slight increase of striatal DA tissue 
levels. Nevertheless, sub-chronic 7-NI treatment induced an even 
stronger regularization of temporal structure of nigral spiking 
activity reducing burst firing of about 60% when compared with the 
control group. These findings are in line with the evidence that 
NOS inhibitors induce catalepsy in rodents [62, 63] and decrease 
exploratory behaviour in rats [64] while both effects disappear after 
only 4 days of NOS inhibition [36, 64-67]. Therefore, the increase 
in DA neurotransmission after 7-NI sub-chronic treatment showed 
by Di Matteo et al. [47] might be the mechanism involved in the 
rapid tolerance development after chronic NOS inhibition. 
Activation of the nigrostriatal system after chronic NO inhibition is 
difficult to explain and is likely to be the final result of different 
effects. For example, an increase in the number of nitrergic neurons 
in the striatum, nucleus accumbens and in the PPT occurred in 
rodents that developed tolerance to the cataleptic effect of the non-
selective NOS inhibitor L-nitro-arginine (L-NOARG) [36, 67]. 
These plastic changes result in partial recovery of striatal NO 
formation [67] and might be involved in the rise in striatal DA 
levels that we observed in our study. Moreover, the increase in the 
number of spontaneously active nigral DA neurons after sub-
chronic 7-NI treatment might be a consequence of the augmented 
excitatory PPT input to the SNc [36], likely mediated by 
acetylcholine (ACh) inasmuch as NOS largely co-localizes with it 
[68]. On the other hand, the decrease in bursting activity seen after 
sub-chronic NO inhibition [47] might depend on the reduced nigral 
NO levels. Indeed, nitrergic neurons are reduced within the SNc 
after L-NOARG sub-chronic treatment [36]. Furthermore, it is 
possible to rule out the involvement of changes in D2 receptors on 
the effects of chronic NOS inhibition inasmuch as it has been 
shown in mice and rats that repeated treatment with L-NOARG 
failed to change striatal D2 binding and D2-mRNA expression in the 
dorsal striatum and SNc [67]. 
 The effect of striatal NO has been investigated on the 
responsiveness of SNc DA neurons to the intermittent electrical 
stimulation of the striatum and orbital prefrontal cortex [69]. 
Increasing NO tone in the striatum counteracted the decrease in 
firing rate of DA cells observed in control animals during 
intermittent stimulation. Additionally, removal of NO tone 
increased the proportion of DA neurons responding to striatal 
stimulation and increased the prevalence of the initial inhibitory 
responses [48, 69]. Thus, it has been proposed that NO may play a 
pivotal role in controlling the delicate homeostatic processes that 
normally provide stability to the DA-nigral system. Indeed, it may 
be capable of dynamically regulating the relative phasic DA 
responsivity via its action on tonic DA levels, in a manner 
dependent on the arousal state of the animal. Under rest, NO 
produced by GLUergic activation of NOS interneurons might 
increase DA release either by intensifying GLU release or by 
influencing the activity of DA transporter, decreasing DA uptake 
and possibly causing a DA reverse release. This increase in tonic 
DA would down-modulate spike-dependent phasic DA release via 
stimulation of the very sensitive DA autoreceptors present on DA 
terminals. In contrast, during behavioural arousal, NO exerts an 
opposite effect on tonic extracellular DA levels that seems to be 
concentration-dependent. The strong production of NO, caused by 
intense GLUergic corticostriatal transmission, would result in the 
inhibition of NMDA receptor function and produce less inhibition 
of phasic DA release via disinhibition of the DA autoreceptors [43]. 
As striatal NO controls DA concentration mutually, striatal NO is 
also under a DAergic influence [70, 71]; indeed both electric and 
chemical stimulation of the SNc elicited a robust surge in striatal 
NO efflux. This release seems to be neuronally dependent, being 
blocked by pretreatment with nNOS inhibitors, and also evoked 
only by high-frequency stimulation that resembles the natural burst 
firing of DA SNc neurons. This last piece of evidence indicates that 
NO efflux occurs only when DA transmission is phasically 
increased and suggests that information transmitted via the 
nigrostriatal pathway during DA cell burst firing may be processed 
and/or amplified by NOS interneurons [70, 71]. DA within the 
striatum could directly modulate NO efflux, exciting NOS 
interneurons through the activation of DA1/5 receptors present on 
their somas and increasing the release of NO [71]. On the other 
hand, DA modulates striatal NO levels via D2 receptors in an 
opposing manner. This inhibitory control seems to be indirect; it is 
plausible that D2 receptors are in fact presynaptically localized on 
GLU and ACh fibres impinging on NOS interneurons [72]. 
 NO might be involved in both effects modulating GLU and 
GABA release in an opposite way. Therefore, NO directly or via a 
modulation of GLU, ACh and GABA striatal levels excites a sub-
population of MSNs projecting to SN exciting SNc DA cells by 
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inhibiting SNr neurons as suggested by West and Grace [69]. At the 
same time, SNc neurons could be directly inhibited by another 
striatal input [73, 74] and indirectly by a proportion of SNr neurons, 
possibly impinging on DA cells that we have shown to be excited 
by NO [75], limiting the excitatory nicotine effect. Thus, striatal 
NO might be crucial in permitting and maintaining nicotine action. 
 It is possible that removal of endogenous NO tone by 7-NI or 
L-NAME treatment might decrease the indirect excitatory pathway 
through the SNc balancing the direct inhibitory one, reducing GLU 
release and leading the SNc neurons to a hypo-functional state. 
Therefore, we propose that the degree of activity of nigrostriatal 
DA neurons may constitute a key factor for the expression of the 
NO/DA interaction, in that enhanced DA synthesis and/or release 
would be required to permit the occurrence of a NO modulatory 
control. In line with this hypothesis is the evidence that striatal NO 
increases only when SNc neurons fire at high frequency and in 
bursts [70, 71, 76]. Indeed, both electric and chemical stimulation 
of the SNc elicited a robust surge in striatal NO efflux [71, 76]. 
This release seems to be neuronally dependent, being blocked by 
pre-treatment with nNOS inhibitors, and also evoked only by high-
frequency stimulation that resembles the natural burst firing of DA 
SNc neurons. This last piece of evidence indicates that NO efflux 
occurs only when DA transmission is phasically increased and 
suggests that information transmitted via the nigrostriatal pathway 
during DA cell burst firing may be processed and/or amplified by 
striatal NOS interneurons [71, 76]. DA within the striatum could 
directly modulate NO efflux, exciting NOS interneurons through 
the activation of D1/5 receptors present on their somas causing an 
increased release of NO [71]. On the other hand, DA modulates 
striatal NO levels via D2 receptors in an opposing manner. This 
inhibitory control seems to be indirect; it is plausible that D2 
receptors are in fact presynaptic on GLU and ACh fibres impinging 
on NOS interneurons [76]. 
 Thus, NO seems to have a general role in controlling the DA 
brain reward and motivation circuitries even being implicated in the 
placebo effect [77]. 
 In summary, neurochemical and electrophysiological results 
demonstrate that NO is involved in both physiological and in drugs 
of abuse processes in the nigrostriatal system. Noticeably, the 
evidence above reviewed indicates that endogenous NO positively 
modulates the efflux of DA in the striatum only when DA 
transmission is increased above basal levels. 
 Clearly, NO modulation of nigrostriatal DA neurotransmission 
is complex and far from being completely understood. 
4.2. NO Modulation of Striatal Activity 
 Several reports have demonstrated two distinct neuron 
populations within the striatum: the interneurons and projecting 
neurons. This classification, obviously based on anatomical 
features, was formerly supported by electrophysiological 
observations showing that striatal neurons differently respond to 
cortical stimulation [78] and to antidromic stimulation [79, 80]. So 
far, by intracellular recordings coupled with intracellular staining it 
has been clearly demonstrated that the projecting neurons, 
anatomically defined as medium spiny neurons, fire at low 
frequencies [81] whilst large aspiny interneurons (about 2–5% of 
striatal neurons), have a sustained and irregular activity [82, 83]. 
 Based on this experience, the extracellular firing analysis 
allows definition of the two classes of striatal neurons both in 
awake and in anesthetized rats [73, 84, 85]. In primates, phasically 
active striatal neurons exhibit clear-cut increases in discharge rate 
occurring in several distinctive forms at specific phases of a task 
[86-88]. Conversely, interneurons exhibit a short lasting decrease in 
response to conditioned stimuli [89]. A more detailed classification 
identifies amongst interneurons [90] parvalbumin-positive 
GABAergic fast-spiking ones (about < 1%), because of their brief 
spike duration [91, 92] separated by GABA interneurons, 
expressing neuropeptides SOM, or NPY or NOS 
(SOM/NPY/NOS+, about 0.6%) and the large aspiny cholinergic 
cells (about 3%). 
 Nitrergic interneurons exert slower neuromodulatory effects on 
their postsynaptic targets rather than fast synaptic effects [93]. The 
lack of synaptic responses in MSNs might be due to a preferential 
release of NO rather than to GABA. D1-class agonists through D1 
family DA receptors elicit depolarization and action potential firing 
in vitro in nitrergic interneurons [94]. Interestingly, as is the case 
with fast spiking interneurons, the excitatory effect of DA on 
persistent low-threshold spiking neurons was also absent in D1 
receptor knockout mice, indicating the involvement of D5 
receptors. In addition, indirect cholinergic effects through M2 
muscarinic ACh receptors have also been reported [95]. 
 Forebrain regions express high levels of cGMP-stimulated 
phosphodiesterase (PDE) [96, 97]. In particular, it has been found 
that the striatonigral MSNs express this enzyme, and it appears to 
provide a mechanism whereby NO from aspiny interneurons, acting 
via cGMP can regulate DA-stimulated cAMP production [98]. 
 NO remains a fascinating but puzzling messenger in the 
nervous system. Although NADPH-d histochemistry, combined 
with immunohistochemistry and in situ hybridization, have clearly 
delineated the cells which synthesize NO and those which express 
its receptor sGC, much remains unknown regarding the significance 
of this signaling system in the CNS. NO actions may be long-acting 
and state dependent. Indeed, measurements of endogenous NO 
production in the brain support this sort of prolonged global action 
for NO in the nervous system. 
 A large amount of evidence has shown that NO, under the 
influence of DA and GLU, plays a role in striatal function by acting 
upon the neuron subtypes [99-101]. NOS-positive fibers synapse 
along with GLUergic and DAergic terminals at level of the MSN 
spines where high levels of sGC were found [102-104], with 
profound functional consequences. For instance, the generation of 
the long-term depression, strictly dependent on NO [100] or the 
spreading of a slow (at 1 Hz) and large amplitude tightly correlated 
activity amongst cortex and striatum [72, 90, 105]. On the other 
hand, NO affects also the activity of the cholinergic large aspiny 
interneurons through the activation of protein kinase G [106]. 
 So far, some studies have addressed the NO-mediated 
electrophysiological response in rat striatum by means of in vivo 
recordings and local microiontophoretic drug administrations. The 
administration of a NO donor strongly inhibits GLU-induced 
excitation of the sporadically firing neurons whilst inhibition of the 
production of endogenous NO produced clear and reproducible 
excitation of glutamate evoked firing [74, 107] (Fig. 2). These 
observations were corroborated and extended by the demonstration 
that the NO/cGMP pathway exerts a powerful control upon the 
striatum by inhibiting the phasically and exciting the tonically 
active neurons [73]. 
4.3. NO Modulation Of Substantia Nigra Pars Reticulata 
 Along with the GPi, the SNr represents the main output 
structure of the basal ganglia directly influencing the activity of 
thalamus and cortex at the end of motor program information 
processing [108-111]. 
 SNr neurons have a tonic firing discharge [112, 113] resulting 
from the inhibitory striatonigral GABAergic afferents [108-110, 
[114] nd the excitatory afferents form the STN [115-117]. The 
presence of NOS-positive neurons has been demonstrated in the 
SNr [118, 119]. Recent evidence shows that the nitrergic system is 
capable of modulating SNr neuronal discharges [120, 121]. The 
data support the idea that NO exerts a tonic excitatory effect upon 
the SNr cells. This conclusion was based on the inhibitory effect of  
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 Fig. (2). Effect of nitric oxide drugs on the firing rate of striatal neurons in 
vivo. Representative rate histogram showing the typical inhibitory effect of 
microiontophoretically applied SIN 1 (20–100 nA) (A) and L-NAME (20–
100 nA) (B) on GLU-induced activation of a striatal neuron. Lines and 
numbers indicate iontophoretic ejection and currents (in nA). Representative 
rate histogram showing that microiontophoretic application of methylene 
blue (50 nA, continuous) (C) prevents the responses to SIN 1 (50–100 nA) 
on GLU-induced activation of a striatal neuron. Lines and numbers indicate 
iontophoretic ejection and currents (in nA). Dashed lines indicate onset and 
offset of GLU pulses. GLU currents were constant throughout each 
recording. Modified from [74]. 
the NOS inhibitor, L-NAME locally applied, suggesting that an NO 
tone is present upon SNr neurons. Furthermore, direct local release 
(by using an NO donor, i.e. 3-morpholino-syndnonimin-
hydrocloride [SIN-1]) of NO caused a statistically significant 
increase in the firing rate of most of the responsive cells. Thus, 
based on these findings and on the peculiar physical characteristics 
of a gaseous neurotransmitter, NO could play a key role in the final 
stage of the so-called “pattern-model” of BG functioning. The 
sequenced involvement of the hyper-direct, direct and indirect 
pathway in the motor program out-flow, implies that at the end of 
the cycle a large part of the thalamus/cortex should be depressed in 
order to reset the system for the other operation. As can be easily 
argued, the GLU-mediated augmentation of NO level within the 
SNr trough the STN, placed in the indirect pathway, can mediate 
the extensive excitation of the BG output, preparing the next step 
for a motor program selection. 
 This hypothesis seems to be corroborated by the finding that 
deep brain stimulation of the STN induced clinical amelioration in a 
PD patient was associated with a clear cut increase of NO tone 
within SNr [122]. 
4.4. NO Modulation of Substantia Subthalamic Nucleus 
 The NO is well known to play a role in modulating the neuronal 
activity of STN neurons. In situ hybridization studies have shown 
that NOS mRNA is expressed in the STN of rodents and humans 
[27, 123]. This neuro-anatomical evidence, suggesting a putative 
role for NO in the modulation of STN neuronal activity, has been 
successively supported by electrophysiological data, showing that 
NO-active drugs are able to alter the basal firing rates of recorded 
neurons in the STN. Thus, systemic injection of the selective NOS 
inhibitor, 7-NI, induced a decrease in basal firing rates of most of 
the recorded neurons in the STN. The same effect was observed 
following the local blockade of NOS activity with L-NAME, 
another NOS inhibitor, applied by microiontophoresis [124, 125]. 
Consistently, local administration by microiontophoresis of SIN-1 
and S-nitroso-glutathione (SNOG), two NO donors, increased the 
discharge rate of the neurons recorded in vivo in the STN. Although 
this evidence might mainly indicate a functional involvement of NO 
in enhancing STN neuronal activity, the modalities through which 
NO modulates neurotransmission within the STN appear to be more 
complex. Indeed, the same authors described how a minority of the 
recorded cells showed an opposite response to the local application 
of NO-active compounds, both NOS inhibitors (L-NAME) and NO 
donors (SIN-1, SNOG) [124, 125]. Furthermore, when the drugs 
were tested on the same neuron, in most of the cases only one of 
them was able to elicit a response. According to the authors, these 
observations might indicate that NO regulates neuronal activity 
within the STN by acting as a neurotransmitter and interacting with 
other neurotransmitter systems (mainly GLU and GABA) at both 
pre and post-synaptic levels. This latter aspect of NO action on 
STN neuronal activity has been supported by some recently 
published data. Indeed, the magnitude of GABA-induced responses 
in the STN in vivo was reduced by local co-application of SNOG 
while, accordingly, it was enhanced by the NOS inhibitor L-
NAME. Moreover, both excitatory and inhibitory responses to 
SNOG and L-NAME, respectively, were reduced by co-application 
of bicuculline, a selective GABAA receptors blocker, thus showing 
an involvement of this receptor subtype in the GABA-NO 
interaction within the STN [126]. Finally, GLUergic afferent fibers 
arising from the cortex represent an important input to this 
structure. A functional GLU-NO interaction within the STN has 
been suggested. Indeed, GLU-induced activation of STN neurons 
was enhanced by the local co-application of SNOG while it was 
attenuated by the NOS inhibitor L-NAME [126], thus showing that 
NO might exert a modulatory action of GLU opposite to GABA. 
The modulation of the GLUergic neurotransmission by this 
unorthodox neurotransmitter has long since been shown in other 
brain structures like the striatum [43]. For example, NO influences 
neuronal excitability by interacting with regulatory sites on the 
NMDA receptors, or by inducing calcium-independent release of 
GLU from synaptic terminals. Finally, NO has been recently shown 
to play an important role in mediating the activation of ATP 
sensitive K+ channels induced by Ca2+ influx through NMDA-gated 
channels [127]. The hyperpolarizing currents activated by ATP 
sensitive K+ channels channels opening appear to play a role in 
counteracting the excessive neuronal activation induced by GLU 
release and regulating the firing pattern of STN neurons. 
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4.5. NO Modulation of Substantia Globus Pallidus 
 The GP represents an important structure of the basal ganglia 
circuitry. So far, few data have been published showing a functional 
involvement of NO in modulating the neuronal activity of the 
neurons within the GP. Electrophysiological recordings in vivo of 
spontaneously active single neurons in the GP showed that the 
systemic injection of 7-NI was able to decrease the basal discharge 
rate in about half of the recorded cells [107]. Consistently, NOS 
inhibition induced by local administration of L-NAME resulted in a 
reduction of the firing activity in most of the neurons tested while, 
accordingly, the NO donor SIN-1 induced an increase of the basal 
neuronal activity following local ejection from the recording pipette 
[107]. Thus, these data clearly indicate a functional excitatory role 
of NO that is likely to be related to a nitrergic modulation of 
GLUergic neurotransmission within the GP. In fact, the increase of 
NO transmission has been shown to enhance GLU-induced 
excitation of GP neuron electrical activity while, consistently, it 
was reduced by the blockade of NOS activity in the GP [128]. 
5. INVOLVEMENT OF NO IN NEURODEGENERATION OF 
DAERGIC NIGROSTRIATAL SYSTEM 
 NO is a Janus-faced molecule and, notwithstanding, the exact 
role (i.e. neuroprotective vs neurotoxic) it plays in 
neurodegenerative disorders is still ambiguous, with the effect 
depending on the redox state of the cellular environment. 
Substantial evidence demonstrates a causative role for NO in the 
degeneration of DAergic neurons of the nigrostriatal pathway in PD 
but the mechanism is still unknown and some data are controversial 
[24, 27, 45, 46, 129-132]. This hypothesis is also supported by 
studies reporting that NOS inhibitors or NOS gene knock-out 
significantly mitigate nigral cell loss in animal experimental models 
[133, 134]. 
 Consistently, NOS polymorphisms which increase expression 
of astroglial iNOS and nNOS have been reported in PD patients and 
in different toxin-induced experimental models of PD. Evidence in 
animal models and in PD patients suggests that NOS is up-
stimulated in the BG nuclei and enhanced NO formation takes place 
after partial injury of the nigrostriatal DAergic system. The exact 
mechanisms of how NO contributes to neurodegenerative diseases 
are not completely understood. Multiple lines of evidence indicate 
that NO is associated with excitotoxicity, DNA damage, and protein 
modifications, which are common pathogenic mechanisms involved 
in multiple neurodegenerative diseases [22]. Nevertheless NO, 
produced by either nNOS or iNOS, plays an important role in DA 
degeneration. iNOS once induced remains active for several hours 
to days and produces NO in 1000-fold greater quantities than the 
constitutive enzyme nNOS. A robust increase in iNOS mRNA 
levels has been observed after lipopolysaccharide, MPTP or 6-
OHDA injection in striatum and SNc [2, 135]. Damage to striatal 
DAergic fibres seems to be mainly mediated by NO produced by 
nNOS, while the damage to nigral DAergic neurons is largely 
inflicted by NO generated by iNOS. Evidence from human post-
mortem studies has revealed an increase of NOS mRNA expression 
only in the MML and in dorsal STN. Instead, a reduction has been 
shown to occur in the striatum although it was not statistically 
significant [24]. Such altered activity of NOS neurons of the MML 
and STN may play a role in the compensatory upregulation of 
nigrostriatal DAergic neurotransmission in PD, but might also exert 
an excitotoxic effect on striatal neurons and nigrostriatal terminals. 
 In animal 6-OHDA-models of PD nNOS expression is reduced 
while a proportion of nNOS nerve fibres in the striatum are 
apparently lost following DAergic deafferentation, resulting in a 
50% decrease in NOS activity, and depression of the NO-cGMP 
pathway [136, 137]. In contrast, Gomes et al. [37] showed that 6-
OHDA lesion induced a significant increase in NOS cell numbers 
in the ipsilateral dorsal striatum while a decrease was seen in the 
ipsilateral SNc and contralateral NAc. 
 A useful experimental approach to study PD in rats is to induce 
degeneration of nigrostriatal DA-containing neurons by perfusing 
1-methyl-4-phenylpyridinium (MPP+) into the striatum and to study 
striatal DA release for two days by microdialysis, the so called 2-
day test-challenge microdialysis method [138]. MPP+ is 
accumulated by DAergic terminals and then retrogradely 
transported in the cell bodies of DAergic neurons, causing cell 
degeneration and loss. Short perfusion of MPP+ induced a 
comparable impairment of DAergic striatal nerve terminals, 
associated with a massive increase in DA efflux 40 min after toxin 
injection, on day 1. A second challenge with MPP+, 24 h later, 
caused a limited output of extracellular DA in MPP+-lesioned rats, 
and this is considered an index of neurotoxin-induced damage. We 
showed that the inhibition of the NO system by pretreatment with 
7-NI can have a protective effect against neuronal damage induced 
by intrastriatal infusion of MPP+ [45]. 7-NI given 1 h before 
perfusion with the neurotoxins, on day 1, partially restored the 
cell’s ability to release DA after the second MPP+ challenge, 
showing a protective effect against MPP+ toxic effects on DAergic 
neurons. 
 Inhibition of the NO system by pretreatment with 7-NI has also 
a protective effect against neuronal damage induced by intra-nigral 
infusion of 6-OHDA using a neurochemical assay on striatal rat 
tissues [46]. 7-NI given 1 h before perfusion with neurotoxin 
partially restored the DA content. Notably, DA levels after 7-NI 
pretreatment were three times higher than those revealed in the 
control 6-OHDA-lesioned rats suggesting an important protective 
effect against the toxin effects on DAergic neurons by NOS 
inhibition. Further confirming the involvement of NO in the DA 
SNc death mechanisms, pretreatment with MOL, halved DA levels 
in the lesioned striata and, most importantly, completely 
counteracted the neuroprotective effect of 7-NI when co-
administrated with it [46]. From these findings, the result that 7-NI 
counteracts the neurotoxicity induced by 6-OHDA nigral-lesion 
while MOL worsens it, clearly indicates that the neuroprotective 
effect of nNOS inhibiton is mainly due to a block in the rise of 
toxic NO. It is likely that NO induces the formation of peroxynitrite 
(NO3¯) produced by its combination with hydroxyl radical (˙OH) 
induced by 6-OHDA [139-141]. Furthermore, NO produces other 
important mediators of neuronal degeneration in the 6-OHDA 
model such as semiquinones, peroxinitrite and 6-OHDA quinine, 
reacting with DA [142] and 6-OHDA [143], respectively. 
 It is known that 6-OHDA induces degeneration of nigrostriatal 
DA-containing neurons being transported in the cell bodies of 
DAergic neurons, causing cell degeneration in a way similar to that 
found in PD probably by the production of reactive oxygen species 
[61, 144]. 6-OHDA induced a compelling impairment of the DA 
nigrostriatal system, associated with a massive decrease of striatal 
DA and DOPAC levels measured 1 week after the surgery. 
Although the aetiology of PD is complex, a significant body of data 
from clinical and experimental models suggests a role for oxidative 
stress as a causative agent inducing DA neurodegeneration [2, 145] 
Thus, PD aetiology could be explained by a genetic susceptibility to 
environmental or endogenous agents, leading to oxidative damage 
in a neuronal population that is naturally under oxidative stress 
[146]. The role of oxidative stress in the pathogenesis of 
MPTP/MPP+-induced DAergic degeneration, has been suggested 
[56, 58, 61, 139-141, 147]. Numerous studies have proposed that 
nNOS inhibitors, including 7-NI, may reduce DAergic neuronal 
degeneration, both in vitro and in vivo through antioxidative 
mechanisms [148-150]. The neuroprotective effect of 7-NI against 
MPP+-induced DA striatal depletion is probably due to a block in 
the rise of the toxic NO3¯ produced by the combination of NO and 
˙OH induced by MPP+, as shown in previous studies [142, 151]. 
NO3¯ is a highly reactive molecule, a potent oxidizing agent known 
to initiate lipid peroxidation in biological membranes, 
hydroxylation, and nitration of aromatic amino acid residues, and 
sulfhydryl oxidation of proteins [143, 152]. Nevertheless, 7-NI did 
8      CNS & Neurological Disorders - Drug Targets, 2011, Vol. 10, No. 7 Pierucci et al. 
not modify extracellular DA output after the first perfusions with 
MPP+, suggesting that it did not affect DA uptake or metabolism 
[46], a piece of evidence in contrast with findings in other studies 
[153, 154]. 
 These possible NOS inhibitor neuroprotective mechanisms are 
consistent with a significant body of data, from clinical and 
experimental models, suggesting a role for oxidative stress as a 
causative agent inducing DA neurodegeneration [150, 155-157]. In 
addition, DA catabolism by MAO induces the formation of 
hydrogen peroxide, thus rendering DA-containing neurons 
particularly liable to oxidative stress [152, 155, 158]. Increased 
nigral DA metabolism, seen in PD, is associated with the 
production of hydrogen peroxide which, together with iron, may be 
converted into ˙OH, reacting very rapidly with almost every 
molecule found in living cells, including DNA, membrane lipids 
and amino acids [153, 156]. The increased DA turnover could itself 
enhance basal production of hydrogen peroxide and cause a 
depletion of reduced glutathione stores, leading to further 
overproduction of toxic ˙OH, as a consequence of impaired 
glutathione scavenging activity. Thus, PD aetiology could be 
explained by a genetic susceptibility to environmental or 
endogenous agents leading to oxidative damage in a neuronal 
population that is naturally under oxidative stress [149]. However, 
other mechanisms by which 7-NI modifies the effects of 6-OHDA 
cannot be ruled out. For example, numerous studies have proposed 
that nNOS inhibitors, including 7-NI, may reduce DAergic 
neuronal degeneration, both in vitro and in vivo through NO-
independent mechanisms [146, 154, 159]. Indeed, 7-NI might act as 
˙OH scavenger and interfere with oxidative stress caused by MPTP 
[58]. Thus, this potent antioxidant action of 7-NI might be involved 
in its neuroprotective effects against 6-OHDA-induced 
neurotoxicity as well. Furthermore, NO can exert its biological 
effects through other mechanisms, such as apoptotic cell death 
induced by 6-OHDA via cGMP, modulating the function of 
monoamine transporters and S-nitrosylation of receptors [160]. 
 In conclusion, NOS inhibitors have a neuroprotective effect on 
different toxin-induced nigrostriatal degeneration in rats, although 
its mechanism of action is still matter for debate. These results 
therefore provide further support that agents that inhibit the NO 
system may prove to be of therapeutic benefit against the ongoing 
loss of DA neurons and motor function that occurs in PD. Although 
these findings provide a potential link between NO activity and PD, 
they have to be interpreted with caution, as the PD models in 
rodents do not reproduce all the neurochemical abnormalities that 
may contribute to depression in PD. In this complex scenario, 
where the interaction of several pathogenic pathways concurs to 
PD, NO seems to represent an important downstream mediator and 
enhancer of molecular events leading to DAergic neuron death. NO 
overproduction appears to be an event that significantly contributes 
to death of DAergic neurons via oxidative damage on cellular 
lipids, proteins and DNA. 
6. NO IMPLICATION ON BG DYSFUNCTION 
 PD is a disorder essentially characterized by a progressive 
slowing of movement (akinesia-bradykinesia) and an increased 
muscle tone (rigidity), frequently associated with resting tremor. 
Although this clinical description refers only to the motor features 
of the disease, ignoring the non-motor symptoms (commonly 
disclosing the disease course), it represents the clinical 
consequences of the degeneration of SNc DAergic neurons, the 
anatomo-pathological core of the PD [129, 161]. 
 The DAergic axons of SNc reach the striatum, modulating at 
this level the processing of movement-related information. DAergic 
denervation triggers aberrant neuroplastic changes in the striatum 
influencing the direct and indirect projections to the output stations 
of the internal segment of the GPi and the SNr. Neurophysiological 
changes consist, as extensively described in the recent literature, of 
abnormally synchronized oscillatory activity at multiple structures 
of the BG–cortical loop. The widespread BG neurons 
synchronization (largely in the beta band spectrum) is generally 
considered a PD hallmark of motor impairment in agreement with 
its high susceptibility to DAergic therapies [162-164]. 
 It has been proposed that NO modulates motor behaviour [43, 
66, 165] and considerable data indicate a direct NO-DA interaction 
either in normal BG function (as explained above) or in BG related 
movement disorders such as PD. For instance the DA agonists, 
cocaine, morphine, substance P or methamphetamine-induced 
hyperlocomotion could be impeded by NOS inhibitors in mice and 
rats [166-168]. Yet, inhibition of NOS also induces catalepsy after 
systemic or intrastriatal injection [65, 66], in agreement with the 
finding that striatal NOS activity is depressed in parkinsonian 
animal models [136, 137] and in human PD [24, 169]. NO synthesis 
seems to be under the control of the phasic/synaptic striatal DA 
transmission [70, 71] and extracellular increase of NO tone within 
the GPi, motor putamen and SNr are correlated with transient 
clinical transition in PD patients [122, 170, 171]. In parkinsonian 6-
OHDA-treated rats different striatal responses to NO regarding the 
different subtypes of neurons can be observed [73]. Spontaneously 
active neurons are more susceptible to NO and less sensitive to 
endogenous NO inhibition, likely linked to a reduction of nNOS in 
DA-denervated striatum [136, 137]. The consequence of the decline 
of NOS-positive neurons following 6-OHDA denervation could be 
responsible for a decrease in tone upon spontaneously active 
neurons that subsequently, by a compensatory mechanism, leads to 
a more evident response to NO in 6-OHDA-lesioned animals. In 
agreement, both the expression and the activity of GC have been 
found to be augmented within striatum of parkinsonian mice [172]. 
 On the other hand, MSNs of DA denervated striatum showed a 
peculiar dichotomy in relation to NO response, since about 40% 
MSNs showed a remarkable NO-mediated excitation. Parkinsonian 
state unmasks a decoupling effect of NO upon a subgroup of 
projection striatal neurons. This effect could be explained on the 
basis of a hypothetically different pattern of expression of PDE 
1b/4/10 following DA-denervation or more consistently in the light 
of the topographical segregation of cholinergic interneurons [173, 
174]. The latter hypothesis is centred on the increased activity of 
cholinergic interneurons in DA-lesioned striatum that might 
facilitate the activity of specific subclass of MSNs [175] by the 
activation of different subtypes of muscarinic receptors. In other 
words, parkinsonian state is associated with an abnormal NOergic 
activity that may also contribute to the pathogenesis of L-DOPA-
induced dyskinesias (LID) [176-179]. 
6.1. Role of NO in L-DOPA-Induced Dyskinesia 
 The abnormal involuntary movements, or dyskinesia, generated 
by prolonged administration of L-DOPA represent one of the major 
challenges facing current therapy for PD [180, 181]. These 
debilitating motor disturbances are all the more problematic 
because L-DOPA, in spite of its introduction several decades ago 
[182], still represents the therapy of choice for the treatment of PD 
[183]. The discovery of pharmacological interventions able to 
counteract LID would therefore represent an important 
breakthrough in the therapy for PD. The design of novel agents for 
the prevention and treatment of LID requires the elucidation of the 
adaptive changes produced in the parkinsonian brain by repeated 
administration of L-DOPA and the assessment of their role in the 
development and expression of this condition [184]. The translation 
of antidyskinetic agents into clinically successful drugs has 
produced limited results yet. The new strategy for antidyskinetic 
drug discovery is based on non-DAergic adjuncts to L-DOPA. They 
should hypothetically be able to treat symptoms LID and PD, 
regulating the aberrant activity of the basal ganglia whilst 
maintaining the L-DOPA efficacy on motor function. Promising 
neurotransmitter targets are the noradrenergic, serotonergic, 
GLUergic, and adenosinergic systems [181, 185]. Recently, some 
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evidence has been also produced in both animal models and in PD 
patients suggesting a contributory role of NO signalling in LID 
[178, 179, 186-189]. Hitherto, the study of NO in the effects of L-
DOPA has produced conflicting results. Despite the fact that early 
evidence failed to reveal any L-DOPA-modulation of striatal NO 
levels [190, 191], a recent microdialysis study showed increased 
production of NO3? although with no changes in either NO3? or 
total NO in mice striatum after L-DOPA administration [192]. 
 Recently, more compelling evidence that an over-activity of 
NO system could contribute to the pathogenesis of LID has been 
obtained by using rodent-models of the disease [178, 179, 186, 
187]. For example, chronic L-DOPA treatment induced FosB 
expression in the striatum D1 MSNs and in NOS-positive striatal 
interneurons in rodent PD-models [178, 193]. L-DOPA increased 
nNOS mRNA levels in the contra- and ipsilateral side to the DA 
lesion of the frontal cortex [193] but did not produce any further 
increases of nNOS protein in the striatum compared to the 6-
OHDA-induced increase [193]. 7-NI and L-NOARG treatment 
prevented dyskinesia-induced by L-DOPA [179,186,193] and 7-NI 
improved motor performance in rats [179,186]. Especially 
noteworthy is also the evidence that 7-NI sub-chronic 
administration was devoid of tolerance to the anti-dyskinetic effect 
[179] differently from its cataleptic action [64], effects on SNc DA 
cell-population electrophysiological activity and DA striatal release 
[47]. The hypothesis that raises NO/GC/cGMP pathway activity in 
the CNS is also supported by some evidence in Parkinsonian 
patients. Indeed, increased levels of NO second messenger cGMP 
in serum [194] and NO3
? in cerebrospinal fluid [195] have been 
detected in PD patients receiving L-DOPA therapy. Nevertheless, 
the precise role of NO in the pathogenesis of such invalidating 
complications remains elusive and recent mounting evidence seems 
to indicate an inhibition of cGMP levels rather than an increase 
after L-DOPA. For instance, Stefani and colleagues [189] in a 
microdialysis study in advanced PD patients reported that acute L-
DOPA administration in two subjects out of six produced a clear 
decrease of GPi cGMP levels. In the other four patients basal 
cGMP levels were not modified by L-DOPA treatment, probably 
because cGMP basal levels were close to the detection limit [189]. 
Moreover, L-DOPA did not affect the NO/sGC/cGMP pathway in 
the mouse MPTP PD model, being capable only of up-regulating 
the expression and activity of nNOS and GC in normal animal to 
the level seen in MPTP-treated mice [177]. Moreover, Giorgi and 
colleagues [196] observed very low levels of cGMP in the cortico-
striatal-pallidal loop at the peak of LIDs in rats with experimental 
hemi-parkinsonism. Interestingly, especially for the possible new 
treatment applications, pretreatment of the dyskinetic animals with 
an unselective PDE inhibitor before L-DOPA treatment effectively 
reduced the severity of the dyskinesias, and partly prevented the 
decrease of cGMP levels in the GP, putamen and the sensorymotor 
cortex [196]. These findings have recently been confirmed by 
Picconi and co-workers [187] using more specific inhibitors for the 
PDE that specifically acts on cGMP metabolism. Given the above, 
PDE inhibitors might represent a new pharmacological target of 
benefit in correcting motor behaviour as well as their potential for 
reducing or ameliorating dyskinetic behaviour during long-term L-
DOPA treatment. Additional experiments are needed to confirm 
these issues. We are optimistic and the future may disclose 
important new avenues for the treatment of LIDs. NO and its 
nucleotide cascade is a promising target that might act on different 
facets of dyskinesia, such as the impairment of striatal plasticity and 
non-DA alterations. The role that cGMP-regulated PDEs play in 
mediating other NO actions deserves further study. Hitherto, this 
attractive hypothesis has not been validated by either non-human 
primates or humans studies. 
 The whole spectrum of NO implication on parkinsonian BG 
activity strongly suggest that in the near future a new molecule able 
to modify NOergic pathway will be a new possible therapeutic 
approach either to motor impairment or in the control of 
complications of long-term exposure to L-DOPA therapy in 
patients with PD. 
CONCLUDING REMARKS 
 Abundant experimental evidence points to complex effects of 
NO in the BG circuits, both directly and via interactions with the 
DAergic, GLUergic and GABAergic systems and its dysfunction is 
involved in the pathophysiology of PD and other motor disorders. 
In recent years, NO and its reactive metabolites have been proposed 
as important actors in the processes leading to neuronal cell death in 
PD both in terms of pro-oxidants and mediators of inflammatory 
responses. Therefore, the blockage of NO synthesis or the 
scavenging of nitrogen reactive species could represent an efficient 
tool against PD progression and/or prevention. Moreover, numerous 
studies point to nitrergic system as a new potential pharmacologic 
approach for the motor manifestations of PD and adjuvant to L-
DOPA therapy. In addition, NO at the levels of limbic structure 
may also contribute to the co-morbid depression in these patients. 
 It is reasonable to believe that in a few years, increased 
understanding regarding the role of NO in the physiopathology of 
circuitry changes in the BG will concur in order to set a rational 
basis for NO-based therapies that are designed not simply to 
manage disabling dyskinesia but to prevent its induction. Strategies 
intended to halt or at least reduce the pace of nigrostriatal loss 
would be likely to change the path that leads to PD, motor 
fluctuations and LID. 
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ABBREVIATIONS 
DAT = Dopamine transporter 
EP = Entopeduncular nucleus 
GSH = Glutathione 
LDTg = Lateraldorsal tegmental nucleus 
LPS = Lipopolysaccharide 
NAc = Nucleus accumbens 
oPFC = Orbital prefrontal cortex 
PV = Parvalbumine 
PPN = Pedunculopontine nucleus 
SMA = Supplementary motor cortex 
MPTP = 1-Methyl 4-phenyl 1,2,3,6-tetrahydropyridine 
MPP+ = 1-Methyl-4-phenilpyridinium ion 
DOPAC = 3,4-Dihydroxy-phenylacetic acid 
SIN-1 = 3-Morpholino-syndnonimin-hydrocloride 
6-OHDA = 6-Hydroxydopamine 
7-NI = 7-nitro-indazolone 
ACh = Acetylcholine 
BG = Basal ganglia 
CNS = Central nervous system 
cGMP = Cyclic guanosine monophosphate 
DA = Dopamine 
DAergic = Dopaminergic 
eNOS = Endothelial nitric oxide synthase 
GP = Globus pallidus 
GPe = Globus pallidus/ external segment 
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GPi = Globus pallidus/ internal segment 
GLU = Glutamate 
GLUergic = Glutamatergic 
˙OH = Hydroxyl radical 
iNOS = Inducible nitric oxide synthase 
GPi = Internal segment of the globus pallidus 
L-ARG = L-arginine 
LID = L-DOPA-induced dyskinesia 
L-NOARG = L-nitro-arginine 
MML = Medial medullary lamina 
MSNs = Medium spiny neurons 
MOL = Molsidomine 
MAO = Monoamine oxidase 
NADPH-d = NADPH-diaphorase 
nNOS = Neuronal nitric oxide synthase 
NPY = Neuropeptide Y 
NADPH = Nicotinamide adenine dinucleotide phosphate 
NOS = Nitric oxide synthase 
NO = Nitric oxide 
NMDA = N-Methyl-D-aspartate 
L-NAME = N?-nitro-L-arginine methyl ester 
PD = Parkinson’s disease 
PPT = Pedunculopontine tegmental nucleus 
NO3¯ = Peroxynitrite 
PDE = Phosphodiesterase 
SNOG = S-Nitroso-glutathione 
sGC = Soluble guanylyl cyclase 
SOM = Somatostatin 
SNc = Substantia nNigra pars compacta 
SNr = Substantia nigra pars reticulatereticulata 
SN = Substantia nigra 
STN = The subthalamic nucleus 
TH = Tyrosine Hydroxylase 
VTA = Ventral tegmental area 
GABA = ?-aminobutyric acid 
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